Obesity, Ozempic, and Medicalization Through Pharmaceuticalization
DOI:
https://doi.org/10.4454/mefisto.10-1.1648Keywords:
Medicalization, Pharmaceuticalization, Ozempic, Semaglutide, ObesityAbstract
Obesity and overweight globally affect billion of people, and have an economic impact measurable in trillion of dollars. In the recent years, two things have changed how we treat and see these conditions. First, the development of semaglutide-based therapies has introduced in the market an effective treatment for obesity that (so far) present drastically reduced side effects compared to previous ones. Second, the consensus of the medical community has slowly converged toward considering obesity a disease. This process is particularly interesting when placed within the discourses over medicalization, i.e. the transformation of non-medical conditions in medical ones, and pharmaeuticalization, i.e. the transformation of human conditions not managed with drugs in ones which are. Pharmaceuticalization has been often considered to follow, logically and temporally, medicalization. This paper presents the impact that semaglutide had on the redefinition of obesity as a disease, and claims that this case shows how pharmaceuticalization can preceed, and shape, medicalization.
Downloads
Published
Issue
Section
License
Copyrights are transferred for 18 months starting publication date from the author(s) to the Publisher. After this period, the content is released under a CC BY-NC-ND 4.0 licence (Attribution-NonCommercial-NoDerivatives 4.0 International).